药物经济学
处方集
医学
可比性
卫生经济学
标准化
医疗保健
重症监护医学
风险分析(工程)
价值(数学)
精算学
公共卫生
家庭医学
计算机科学
业务
经济
数学
护理部
组合数学
操作系统
经济增长
机器学习
作者
Gary C. Brown,Melissa M. Brown,Hilary F. Brown,Ashlee N. Godshalk
出处
期刊:Current Opinion in Ophthalmology
[Ovid Technologies (Wolters Kluwer)]
日期:2007-04-13
卷期号:18 (3): 206-211
被引量:2
标识
DOI:10.1097/icu.0b013e328129089e
摘要
Purpose of review To describe pharmacoeconomics and its relationship to drug interventions. Recent findings Pharmacoeconomics is the branch of economics which applies cost-minimization, cost-benefit, cost-effectiveness and cost-utility analyses to compare the economics of different pharmaceutical products or to compare drug therapy to other treatments. Among the four instruments, cost-utility analysis is the most sophisticated, relevant and clinically applicable as it measures the value conferred by drugs for the monies expended. Value-based medicine incorporates cost-utility principles but with strict standardization of all input and output parameters to allow the comparability of analyses, unlike the current situation in the healthcare literature. Summary Pharmacoeconomics is assuming an increasingly important role with regard to whether drugs are listed on the drug formulary of a country or province. It has been estimated that the application of standardized, value-based medicine drug analyses can save over 35% from a public healthcare insurer drug formulary while maintaining or improving patient care.
科研通智能强力驱动
Strongly Powered by AbleSci AI